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ments prior to the start of the conditioning regimen and 8
after engraftment at two treatments every twoweeks. All pts
also received tacrolimus and methotrexate and 8 also
received ATG. 20 pts (13 males, ages 28 e 57) were enrolled.
All pts underwent a MA HCT (15 Bu-Cy and 5 Cy-TBI), 11 from
matched unrelated, 5 from related and 4 from mismatched
unrelated donors.15 had AML orMDS and 5 ALL or NHL. 4 pts
died before day 100 (RSV n¼1, GvHD and sepsis n¼1 and
relapse n¼2). 12 pts received all the 10 planned ECP treat-
ments while 8 received 2-6 of the treatments due to death
before day 100 (n¼4), relapse (n¼2), and withdrawal due to
iv access issues (n¼2). 4 patients required blood products
before ECP. AGvHD grade 2 e 4 occurred in 12 of 19 (63%)
evaluable pts while grade 3-4 occurred in 4 (21%). 4 of 14
surviving pts developed chronic GvHD (28%), 3 extensive and
1 limited. Two pts died from cGvHD. 14 patients (70%) are
alive from 5 months to 30 months post HPCT. PBMCs were
collected before ECP therapy and three months post-HPCT.
T cells were analyzed for CD45RO, B cells for IgD, and CD4+
T cells for FoxP3. In patients who developed GvHD, fewer
T cells expressed CD45RO, but more B cells had isotype class-
switched. Patients who did not develop GvHD hadmore Treg
cells (ﬁg). These data indicate ECP may be effective as pro-
phylactic therapy for cGvHD and should be further investi-
gated. The pre-transplant lymphocyte phenotype might
predict post-transplant lymphocyte activity and the efﬁcacy
of ECP as a prophylactic therapy.Figure 1. Progression-free survival for patients with advanced CML treated
with a haploidentical transplant at MD Anderson Cancer Center.325
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Background: Allogeneic stem transplantion in Chronic
Myeloid Leukemia (CML) is reserved for patients who have
accelerated phase (AP), are in blast crisis (BP), chronic phase
CML patients that have failed second-generation tyrosine
kinase inhibitors (TKIs), and those who have developed
resistant mutations to TKI such as T315I. Haploidenticalhematopoietic Stem Cell transplantation (HaploSCT) is an
alternative treatment option for patients without a matched
donor. Post-transplant cyclophosphamide (PTCy), in addition
to tacrolimus and mycophenolate, has been effective in
preventing GVHD and was associated with lower treatment-
related mortality in this type of transplant. However,
outcomes for patients with CML using this approach are
unknown, we therefore report on our experience using
haploidentical transplantation for a cohort of advanced CML
patients treated at our institution.
Patients and Methods: We performed a retrospective chart
review of patients with advanced CML who received a hap-
loidentical stem cell transplant at the MD Anderson Cancer
Center after January 2009. The objectives of this analysis
were to determine rates of engraftment, incidence of GVHD,
treatment-related mortality, relapse rates and survival. The
conditioning regimen consisted of melphalan 140mg/m2
(1 patient had 100mg/m2), thiotepa 5-10 mg/kg and ﬂudar-
abine 160mg/m2 total dose. GVHD prophylaxis consisted of
post-transplant cyclophosphamide followed by tacrolimus
andMMF as previously reported. All but one patient received
bone marrow as stem cell source.
Results: Ten patients with advanced CML were treated dur-
ing this time period. The median number of prior medical
therapies including TKIs was 3. All patients engrafted neu-
trophils after a median of 18 days, with 100% donor cells on
chimerism, and achieved remission post-transplant. Acute
grade 2-4 GVHD occurred in 30% (no grade 3 -4), and overall
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patients relapsed and died, 3/4 who were not in chronic
phase at the time of transplant. No patient died of treatment-
related mortality. 71% of patients transplanted in second
chronic phase remained in molecular remission at the last
follow-up. After a median follow-up of 22 months median
PFS had not been reached; 6 patients (60%) are alive, 5 are in
complete molecular remission and one with low level PCR
positivity (Figure 1).
Conclusion: Our results suggest that HaploSCT can produce
durable complete remissions with minimal toxicity for pa-
tients with advanced CML, and that treatment outcomes are
comparable with matched transplantation as recently re-
ported by us in abstract format by Ahmed et al. Larger
studies, with longer follow-up and comparison to other
donor sources are needed to better assess this approach.326
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Introduction: The safety of stem cell mobilization using high
dose granulocyte-colony stimulating factor has not been
established in stem cell donors with sickle cell trait (SCT).
Herein, we aimed to estimate the incidence of adverse events
related to stem cell mobilization in donors with SCT in
comparison to normal donors.
Methods: In this retrospective matched case control study,
we enrolled 12 consecutive stem cell transplant donors with
SCT (cases) and 12 age and gender matched donors with
normal Hemoglobin electrophoresis (controls) between
January 2007 and May 2013. We reviewed the health records
for reported adverse events. We compared the incidence of
adverse events using the appropriate statistical tests. We use
ﬁlgrastim 10 microgram/kg subcutaneously daily for 6 days
and collect the peripheral blood stem cells on day 6 after 2
hours of the last ﬁlgrastim dose.
Results: Both groups had similar baseline characteristics.
There were 6 males and 6 females in each group, with mean
age of 17 years in SCT donors and 19 years in non-SCT donors.
The mean weight was 57 and 63 Kg for SCT and non-SCT
donors respectively. There was no statistically signiﬁcant
difference between the two groups in the reported adverse
events including bone pain, headache, myalgia and para-
sthesia. In the SCT donors group, three donors had headache,
one had bone pain and one had parasthesia. In the non-SCT
control group, two donors had headache, two had bone pain
and one had myalgia. None of donors had chest pain, sei-
zures, bleeding, nausea, vomiting, infection, splenic rupture,
carpal-tunnel syndrome or blood transfusion. There were no
reported deaths. The mean CD34 positive cell count
measured on day 6 of mobilization was 98.2 x 106 /L (+/-
87.10) in the SCT group compared to 81.87 x 106 /L (+/- 78.71)
in the non-SCT control group (P¼0.81).
Conclusion: The observed incidence of adverse events in
SCT-donors in relation to stem cell mobilization is very low,
and is not higher than in non-SCT donors. Donors with SCT
can be considered for stem cell mobilization. However, pro-
spective and larger studies are needed to conﬁrm the safety
of stem cell mobilization in this group.327
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Introduction: Allogeneic transplants using hematopoietic
stem cells from unrelated donors (alloHSCT) have become
more common than related transplants. Matched unrelated
alloHSCT in Canada are facilitated by the OneMatch Stem
Cell and Marrow Network. Patients may undergo a second
unrelated alloHSCT with prior conditioning or simply
receive an infusion of cells from an unrelated donor [donor
lymphocyte infusion (DLI)]. There have been few studies
examining the outcomes of second unrelated alloHSCT or
DLI in large numbers of patients and none involving the
Canadian registry.
Methods: We examined a consecutive series of Canadian
patients who received a second unrelated alloHSCT or DLI
through OneMatch during the period between January 1st
2002 and December 31st 2011. We collected information
about disease type and status at the time of ﬁrst trans-
plant, ﬁrst transplant date, indication for and date of sec-
ond transplant or DLI, and the graft types (bone marrow,
G-CSF stimulated peripheral blood or unstimulated DLI)
and conditioning regimens for both transplants. Survival
status, disease status, and engraftment status at most
recent follow-up were also collected. Donor and recipient
information including year of birth and weight was also
collected.
Results: There were 128 consecutive Canadian patients who
received a second unrelated alloHSCT or DLI during the
period speciﬁed. Median age of recipients was 37 (range:
2-68). There were 73 males, 36 females, and 19 patients
whose sex was unknown. The most common indication for
second transplant or DLI was disease relapse (n¼68, 53%),
followed by graft failure (n¼37, 29%). The most common
disease for which the ﬁrst transplant was undertaken was
acute myeloid leukemia (n¼37, 29%), followed by lympho-
proliferative disorders (n¼29, 23%). The most common graft
type for second transplant was unstimulated peripheral
blood (65, 51%), and 101 of 128 (79%) second transplants
used the same donor as for the ﬁrst transplant. Median
survival was 1.03 years (95% CI ¼ 0.87-1.69). Median time
between transplants was 10.56 months (0.6-105.72).
Patients whose time between transplants was above the
median were more likely to be alive at last follow-up,
(p¼0.029) and they exhibited higher survival in the ﬁrst
year post-transplant. No other factors were found to sig-
niﬁcantly affect survival.
This study is the ﬁrst to examine a consecutive series of
unselected patients receiving a second donation of hemato-
poietic stem cells from an unrelated donor using the Cana-
dian registry. Survival is comparable to previous studies
using the American (Schriber et al., 2010) and German
(Platzbecker et al., 2008) registries. This study shows that
outcomes do not differ signiﬁcantly based on disease, age,
gender, conditioning regimen, and graft type. Further studies
will be needed to identify factors that better predict out-
comes when utilizing this scarce resource.
